405
Participants
Start Date
June 14, 2019
Primary Completion Date
May 24, 2024
Study Completion Date
August 13, 2024
Experimental: Tezepelumab
Tezepelumab subcutaneous injection
Placebo
Placebo subcutaneous injection
Research Site, Quezon City
Research Site, Iloilo City
Research Site, Hohhot
Research Site, Baotou
Research Site, Suwon
Research Site, Cheongju-si
Research Site, Daegu
Research Site, Jeonju
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Shengyang
Research Site, Shenyang
Research Site, Changchun
Research Site, Hefei
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Nanjing
Research Site, Xuzhou
Research Site, Xuzhou
Research Site, Yangzhou
Research Site, Jinan
Research Site, Zibo
Research Site, Weifang
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Huzhou
Research Site, Linhai
Research Site, Jinhua
Research Site, Wenzhou
Research Site, Nanchang
Research Site, Fuzhou
Research Site, Quanzhou
Research Site, Chongqing
Research Site, Chongqing
Research Site, Chongqing
Research Site, Changsha
Research Site, Changsha
Research Site, Hengyang
Research Site, Wuhan
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Shenzhen
Research Site, Zhuhai
Research Site, Nanning
Research Site, Guiyang
Research Site, Zunyi
Research Site, Haikou
Research Site, Chengdu
Research Site, Kunming
Research Site, Xi'an
Research Site, Lanzhou
Research Site, Xining
Research Site, Ürümqi
Research Site, Beijing
Research Site, Nanjing
Research Site, Guangzhou
Research Site, Hohhot
Research Site, Linyi
Research Site, Shijiazhuang
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
AstraZeneca
INDUSTRY